Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2015

View Archived Issues

Eisai reflects on accomplishments of first quarter of fiscal 2015

Oasmia reports results for Paclical compared to Abraxane in metastatic breast cancer

ProtoKinetix updates on studies on AAGP in pancreatic islet transplantation

New cell-based BBB model for studying drug transport in AD

FDA awards orphan drug status to Insys's cannabidiol for infantile spasms

Karuna Pharmaceuticals receives Wellcome Trust funding to develop KarXT for schizophrenia

Ultragenyx begins phase II study of recombinant human beta-glucuronidase

Vtesse reports preliminary data from ongoing phase I study of VTS-270

Enrollment begins in U.S. phase III trial of ECCS-50

Theravance Biopharma receives FDA fast track designation for TD-8954

InMed Pharmaceuticals reports in vitro study results for INM-750

Pseudo-glycodendrimer blocks HIV transinfection

GW Pharmaceuticals receives FDA fast track and EMA orphan status for intravenous cannabidiol

GSK initiates first-in-human study of RSV vaccine GSK-3389245A

Promising antiatherosclerosis activity of human FOXP3 gene therapy in mice

Immunotherapy collaboration between Juno Therapeutics and Celgene becomes effective

Apodemus AB patents antivirals

Egis Pharmaceuticals discloses dual GABA(A) agonist/antagonists

Advaxis receives prostate cancer charity grants to develop ADXS-PSA

Aerie forms ophthalmic delivery collaboration with GrayBug

Marathon discloses plans for NDA of deflazacort for Duchenne muscular dystrophy

FORUM Pharmaceuticals synthesizes gamma-secretase modulators

Cleave Biosciences reports development of p97 complex inhibitors

Dicerna's DCR-PH1 receives orphan drug designation from the EMA

FDA approves IND application for Valor's IGN-002

TiGenix and FDA agree design for phase III trial of Cx-601 in perianal fistula

Gammaplex approved for use in pediatric patients

Keystone Nano awarded NIAID contract to develop RNAi therapeutic for influenza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...